Barinthus Biotherapeutics plc.

Barinthus Bio is a clinical-stage biopharmaceutical company focused on developing new immunotherapeutic drug candidates for autoimmune and inflammatory diseases. The company prioritizes its SNAP-TI platform, designed to promote immune tolerance by guiding T cells to reduce inflammation and restore natural immune non-responsiveness to healthy tissue. Its lead candidate, VTP-1000, aims to restore immune non-responsiveness to gluten in celiac disease patients and is currently in a Phase 1 clinical trial. Barinthus Bio believes the SNAP-TI platform could impact multiple other autoimmune and inflammatory conditions. The company is also exploring partnerships for VTP-300, a product candidate for chronic hepatitis B (CHB). VTP-300 uses viral vector platform technologies, Chimpanzee Adenovirus Oxford (ChAdOx) and Modified Vaccinia Ankara (MVA), to increase disease-specific CD8+ T cells. VTP-300 is a Phase 2 immunotherapeutic treatment modality intended as part of a regimen to achieve functional cure in chronically infected hepatitis B patients. The company leverages its understanding of T cell function, which are key to the body's ability to identify and respond to threats through antigen recognition.